Hepatitis B virus epidemiology

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 5, 2015, Pages

  MacLachlan, Jennifer H ^a,b   Cowie, Benjamin C ^a,b,c  

^a PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE COURSE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNITY; INDIGENOUS PEOPLE; MIXED INFECTION; MORTALITY; NONHUMAN; PREVALENCE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; COMPLICATION; GENETICS; HEPATITIS B, CHRONIC; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; RISK FACTOR; VIROLOGY;

HEPATITIS B VIRUS;

VIRUS DNA;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RISK FACTORS;

EID: 84930505192     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a021410     Document Type: Article

References (77)

1. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. 2006. Causes of death after diagnosis of hepatitis B or hepatitis C infection: A large community-based linkage study. Lancet 368: 938-945
2. Arankalle VA, Gandhi S, Lole KS, Chadha MS, Gupte GM, Lokhande MU. 2011. An outbreak of hepatitis B with high mortality in India: Association with precore, basal core promoter mutants and improperly sterilized sy- ringes. J Viral Hepat 18: e20-e28
3. Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. 2007. Sytematic review and meta-analysis of prevalence of hep- atitis B in India. Indian Pediatr 44: 663-674
4. Blumberg BS, Alter HJ, Visnich S. 1965. A “new” antigen in leukemia sera. JAMA 191: 541-546
5. Centers for Disease Control. 2012. Hepatitis B—2012 Yellow Book. wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-b
6. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855-1859
7. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, et al. 2009. Decreased incidence of hepatocellular carcinoma in hepatitis B vac- cinees: A 20-year follow-up study. J Natl Cancer Inst 101: 1348-1355
8. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73
9. Chen CF, Lee WC, Yang HI, Chang HC, Jen CL, Iloeje UH, Su J, Hsiao CK, Wang LY, You SL, et al. 2011. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroen- terology 141: e1242
10. Cho LY, Yang JJ, Ko KP, Park B, Shin A, Lim MK, Oh JK, Park S, Kim YJ, Shin HR, et al. 2011. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Sys- tematic review and meta-analysis. Int J Cancer 128: 176-184
11. Cowie BC, Carville KS, MacLachlan JH. 2013. Mortality due to viral hepatitis in the Global Burden of Disease Study 2010: New evidence of an urgent global public health priority demanding action. Antivir Ther 18: 953-954
12. Davies J, Littlejohn M, Locarnini SA, Whiting S, Hajkowicz K, Cowie BC, Bowden DS, Tong SY, Davis JS. 2013. The molecular epidemiology of hepatitis B in the indigenous people of Northern Australia. J Gastroenterol Hepatol 28: 1234-1241
13. Donato F, Boffetta P, Puoti M. 1998. A meta-analysis of epidemiological studies on the combined effect of hepa-titis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75: 347-354
14. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. 1993. The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci 253: 197-201
15. El-Serag HB. 2012. Epidemiology of viral hepatitis and he-patocellular carcinoma. Gastroenterology 142: e1261
16. El-Serag HB, Kanwal F. 2014. Epidemiology of hepatocellu-lar carcinoma in the United States: Where are we? Where do we go? Hepatology 60: 1767-1775
17. Fattovich G, Bortolotti F, Donato F. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progres-sion and prognostic factors. J Hepatol 48: 335-352
18. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Math-ers C, Rebelo M, Parkin DM, Forman D, Bray F. 2012. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France
19. Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stor- naiuolo G, Lobello S, Sagnelli E, Brunetto MR, Rizzetto M. 2000. Chronic hepatitis D: A vanishing disease? A multicenter Italian study. Hepatology 32: 824-827
20. Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiara-monte M, Stroffolini T, Colucci G, Rizzetto M. 2003. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol 39: 1036-1041
21. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. 2005. A mathematical model to estimate global hep-atitis B disease burden and vaccination impact. Int J Epi- demiol 34: 1329-1339
22. Graham S, Guy RJ, Cowie B, Wand HC, Donovan B, Akre SP, Ward JS. 2013. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: A systematic review and meta- analysis. BMC Infect Dis 13: 403
23. Gust ID. 1996. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 38: S18-S23
24. Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. 2004. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: Implications for immunisation policy. J Clin Virol 29: 211-220
25. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, Bulkow LR, Wainwright RB. 2000. Elim- ination of new chronic hepatitis B virus infections: Re- sults of the Alaska immunization program. J Infect Dis 181: 413-418
26. Hughes SA, Wedemeyer H, Harrison PM. 2011. Hepatitis delta virus. Lancet 378: 73-85
27. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130: 678-686
28. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CACancer J Clin 61: 69-90
29. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. 2012. HIV- HBV coinfection—A global challenge. N Engl J Med 366: 1749-1752
30. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. 2012. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 56: 422-433
31. Kramvis A, Clements CJ. 2010. Implementing a birth dose of hepatitis B vaccine for home deliveries in Africa—Too soon? Vaccine 28: 6408-6410
32. Kramvis A, Kew MC. 2005. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 12: 456-464
33. Kramvis A, Kew M, Francois G. 2005. Hepatitis B virus genotypes. Vaccine 23: 2409-2423
34. Landrum ML, Hullsiek KH, Chun HM, Crum-Cianflone NF, Ganesan A, Weintrob AC, Barthel RV, O’Connell RJ, Agan BK. 2011. The timing of hepatitis B virus (HBV) immunization relative to human immunodefi- ciency virus (HIV) diagnosis and the risk of HBV infec- tion following HIV diagnosis. Am J Epidemiol 173: 84-93
35. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107
36. Lemoine M, Nayagam S, Thursz M. 2013. Viral hepatitis in resource-limited countries and access to antiviral thera-pies: current and future challenges. Future Virol 8: 371-380
37. Li D, Long Y, Wang T, Xiao D, Zhang J, Guo Z, Wang B, Yan Y. 2013. Epidemiology of hepatitis C virus infection in highly endemic HBV areas in China. PLoS ONE 8: e54815
38. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, et al. 2009. Epidemiological serosurvey of hepatitis B in China—Declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: 6550-6557
39. Lin CL, Kao JH. 2015. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med 5: a021436
40. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: Update 2009. Hepatology 50: 661-662
41. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095-2128
42. MacLachlan JH, Cowie BC. 2012. Liver cancer is the fastest increasing cause of cancer death in Australians. Med J Aust 197: 492-493
43. MacLachlan JH, Allard N, Towell V, Cowie BC. 2013. The burden of chronic hepatitis B virus infection in Australia, 2011. Aust NZ J Public Health 37: 416-422
44. Mahoney FJ. 1999. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 12: 351-366
45. Marschall T, Kretzschmar M, Mangen MJ, Schalm S. 2008. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol 20: 1214-1225
46. McMahon BJ. 2009. The influence of hepatitis B virus ge- notype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 3: 334-342
47. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV sero- prevalence. Hepatology 57: 1333-1342
48. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, et al. 2014. Global, regional, and national incidence and mortality for HIV, tuberculosis, and ma- laria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 384: 1005-1070
49. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. 2011. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378: 571-583
50. Nguyen VT, Law MG, Dore GJ. 2009. Hepatitis B-related hepatocellular carcinoma: Epidemiological characteris- tics and disease burden. J Viral Hepat 16: 453-463
51. Oh JK, Shin HR, Lim MK, Cho H, Kim DI, Jee Y, Yun H, Yoo KY. 2012. Multiplicative synergistic risk of hepatocellular carcinoma development among hepatitis B and C co- infected subjects in HBV endemic area: A community- based cohort study. BMC Cancer 12: 452
52. Ott JJ, Stevens GA, Groeger J, Wiersma ST. 2012. Global epidemiology of hepatitis B infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vac- cine 30: 2212-2219
53. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. 2010. Incidence of hepatocellular carcinoma in chron-ic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol 53: 348-356
54. Plymoth A, Viviani S, Hainaut P. 2009. Control of hepato- cellular carcinoma through hepatitis B vaccination in ar-eas of high endemicity: Perspectives for global liver can- cer prevention. Cancer Lett 286: 15-21
55. Previsani N, Lavanchy D. 2002. Hepatitis B. Department of Communicable Diseases Surveillance and Response, World Health Organisation, Geneva
56. Puoti M, Manno D, Nasta P, Carosi G. 2008. Hepatitis B virus and HIV coinfection in low-income countries: Un-met needs. Clin Infect Dis 46: 367-369
57. Rizzetto M. 2009. Hepatitis D: Thirty years after. J Hepatol 50: 1043-1050
58. Rizzetto M, Ponzetto A, Forzani I. 1990. Hepatitis delta virus as a global health problem. Vaccine 8: S10-S14; discussion S21-S23
59. Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. 2005. The New Zealand Hepatitis B Screening Pro-gramme: Screening coverage and prevalence of chronic hepatitis B infection. NZ Med J 118: U1345
60. Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. 2014. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 20: 7635-7643
61. Salleras L, Dominguez A, Bruguera M, Cardenosa N, Batalla J, Carmona G, Navas E, Taberner JL. 2005. Dramatic decline in acute hepatitis B infection and disease inci- dence rates among adolescents and young people after 12 years of a mass hepatitis B vaccination programme of pre-adolescents in the schools of Catalonia (Spain). Vac- cine 23: 2181-2184
62. Shadur B, Maclachlan J, Cowie B. 2013. Hepatitis D virus in Victoria 2000 - 2009. Intern Med J 43: 1081-1087
63. Shi J, Zhu L, Liu S, Xie WF. 2005. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 92: 607-612
64. Sulkowski MS. 2008. Management of hepatic complications in HIV-infected persons. J Infect Dis 197: S279-S293
65. Tan A, Koh S, Bertoletti A. 2015. Immune response in HBV infection. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a021428
66. Thio CL. 2009. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 49: S138-S145
67. Thompson ND, Perz JF, Moorman AC, Holmberg SD. 2009. Nonhospital health care-associated hepatitis B and C vi- rus transmission: United States, 1998 - 2008. Ann Intern Med 150: 33-39
68. Trépo C, Chan HL, Lok A. 2014. Hepatitis B virus infection. Lancet doi: 10.1016/S0140-6736(14)60220-8
69. United Nations Statistics Division. 2013. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. United Nations Statistics Division, unstats.un.org/unsd/ default.htm
70. Viana S, Parana R, Moreira RC, Compri AP, Macedo V. 2005. High prevalence of hepatitis B virus and hepatitis D virus in the Western Brazilian Amazon. Am J Trop Med Hyg 73: 808-814
71. Viviani S, Carrieri P, Bah E, Hall AJ, Kirk GD, Mendy M, Montesano R, Plymoth A, Sam O, Van der Sande M, et al. 2008.20 years into the Gambia Hepatitis Intervention Study: Assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver can- cer. Cancer Epidemiol Biomarkers Prev 17: 3216-3223
72. Wedemeyer H. 2010. Re-emerging interest in hepatitis delta: New insights into the dynamic interplay between HBV and HDV. J Hepatol 52: 627-629
73. Wedemeyer H, Heidrich B, Manns MP. 2007. Hepatitis D virus infection—Not a vanishing disease in Europe! Hep-atology 45: 1331-1332; author reply 1332-1333
74. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW. 2008. Recommendations for identification and public health management of per- sons with chronic hepatitis B virus infection. MMWR Recomm Rep 57: 1-20
75. Wu Q, Liu Q. 2012. Do hepatitis B virus and hepatitis C virus co-infections increase hepatocellular carcinoma oc-currence through synergistically modulating lipogenic gene expression? Hepatol Res 42: 733-740
76. Zheng Y, Lu Y, Ye Q, Xia Y, Zhou Y, Yao Q, Wei S. 2011. Should chronic hepatitis B mothers breastfeed? A meta analysis. BMC Public Health 11: 502
77. Zoulim F, Durantel D. 2015. Antiviral therapies and pros- pects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a021501